AN2 Therapeutics Inc., a biopharmaceutical company specializing in novel small molecule therapeutics, has announced its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $6.5 million, a significant improvement from the $14.4 million net loss reported in the same period of 2024. General and Administrative expenses increased slightly to $4.0 million from $3.7 million in the previous year, attributed to higher professional and outside services expenses. Interest income decreased to $0.8 million from $1.4 million, reflecting lower cash balances and interest rates. The company's cash, cash equivalents, and investments stood at $71.2 million as of June 30, 2025. AN2 Therapeutics projects that this cash position will fund operations into 2028. Research and Development expenses were notably reduced to $3.2 million from $12.1 million in 2024 due to a decrease in clinical trial expenses and the termination of the EBO-301 clinical study. In terms of business updates, AN2 Therapeutics made progress in its oncology programs, expecting to announce two development candidates within the next 12 months. The company also commenced dosing in a Phase 1 FIH clinical trial for Chagas Disease and continues its global health initiatives, including projects on tuberculosis and malaria, funded by a Gates Foundation grant.